28086772|t|Scutellaria barbata D. Don extract inhibits the tumor growth through down-regulating of Treg cells and manipulating Th1 / Th17 immune response in hepatoma H22 -bearing mice
28086772|a|Previous studies showed Scutellaria barbata D. Don extract (SBE) is a potent inhibitor in hepatoma and could improve immune function of hepatoma H22 -bearing mice. However, the immunomodulatory function of SBE on the tumor growth of hepatoma remains unclear. This study aimed to investigate the anti-tumor effects of SBE on hepatoma H22 -bearing mice and explore the underlying immunomodulatory function. The hepatoma H22 -bearing mice were treated by SBE for 30 days. The effect of SBE on the proliferation of HepG2 cells in vitro, the growth of transplanted tumor, the cytotoxicity of natural killer (NK) cells in spleen, the amount of CD4(+)CD25(+)Foxp3(+) Treg cells and Th17 cells in tumor tissue, and the levels of IL-10, TGF-β, IL-17A, IL-2, and IFN-γ in serum of the hepatoma H22 -bearing mice was observered. IL-17A was injected to the SBE treated mice from day 9 post H22 inoculation to examine its effect on tumor growth. SBE treatment inhibited the proliferation of HepG2 cells in vitro with a dose-dependent manner and significantly suppressed the tumor growth of hepatoma H22 -bearing mice. Meanwhile, it increased NK cells' cytotoxicity in spleen, down-regulated the amount of CD4(+)CD25(+)Foxp3(+) Treg cells and Th17 cells in tumor tissue, and decreased IL-10, TGF-β, and IL-17A levels (P < 0.01) whereas increased IL-2 and IFN-γ levels (P < 0.01) in the serum of hepatoma H22 -bearing mice. Moreover, administration of recombinant mouse IL-17A reversed the anti-tumor effects of SBE. SBE could inhibit the proliferation of HepG2 cells in vitro. Meanwhile, SBE also could inhibit the growth of H22 implanted tumor in hepatoma H22 -bearing mice, and this function might be associated with immunomodulatory activity through down-regulating of Treg cells and manipulating Th1 / Th17 immune response.
28086772	0	34	Scutellaria barbata D. Don extract	T123	C1999758
28086772	35	43	inhibits	T052	C3463820
28086772	48	60	tumor growth	T191	C0598934
28086772	69	84	down-regulating	T044	C0013081
28086772	88	98	Treg cells	T025	C0039198
28086772	103	115	manipulating	T040	C2584326
28086772	116	119	Th1	T043	C1155080
28086772	122	142	Th17 immune response	T040	C3156592
28086772	146	158	hepatoma H22	T025	C0677626
28086772	168	172	mice	T015	C0025929
28086772	197	231	Scutellaria barbata D. Don extract	T123	C1999758
28086772	233	236	SBE	T123	C1999758
28086772	250	259	inhibitor	T121,T123	C0018282
28086772	263	271	hepatoma	T191	C0023903
28086772	290	305	immune function	T042	C1817756
28086772	309	321	hepatoma H22	T025	C0677626
28086772	331	335	mice	T015	C0025929
28086772	350	375	immunomodulatory function	T044	C1148560
28086772	379	382	SBE	T123	C1999758
28086772	390	402	tumor growth	T191	C0598934
28086772	406	414	hepatoma	T191	C0023903
28086772	423	430	unclear	T033	C3845108
28086772	437	442	study	T062	C2603343
28086772	452	463	investigate	T169	C1292732
28086772	468	478	anti-tumor	T080	C2986475
28086772	479	486	effects	T080	C1280500
28086772	490	493	SBE	T123	C1999758
28086772	497	509	hepatoma H22	T025	C0677626
28086772	519	523	mice	T015	C0025929
28086772	551	576	immunomodulatory function	T044	C1148560
28086772	582	594	hepatoma H22	T025	C0677626
28086772	604	608	mice	T015	C0025929
28086772	614	621	treated	T169	C1522326
28086772	625	628	SBE	T123	C1999758
28086772	636	640	days	T079	C0439228
28086772	646	655	effect of	T080	C1704420
28086772	656	659	SBE	T123	C1999758
28086772	667	680	proliferation	T043	C0596290
28086772	684	695	HepG2 cells	T025	C2717940
28086772	696	704	in vitro	T080	C1533691
28086772	710	738	growth of transplanted tumor	T191	C0598934
28086772	744	785	cytotoxicity of natural killer (NK) cells	T043	C1159807
28086772	789	795	spleen	T023	C0037993
28086772	801	807	amount	T081	C1265611
28086772	811	843	CD4(+)CD25(+)Foxp3(+) Treg cells	T121	C3830403
28086772	848	858	Th17 cells	T025	C2936411
28086772	862	874	tumor tissue	T024	C0475358
28086772	884	890	levels	T080	C0441889
28086772	894	899	IL-10	T116,T129	C3179724
28086772	901	906	TGF-β	T116,T129,T192	C0076930
28086772	908	914	IL-17A	T116,T192	C1705947
28086772	916	920	IL-2	T116,T129	C0021756
28086772	926	931	IFN-γ	T116,T192	C0211279
28086772	935	940	serum	T031	C0229671
28086772	948	960	hepatoma H22	T025	C0677626
28086772	970	974	mice	T015	C0025929
28086772	991	997	IL-17A	T116,T192	C1705947
28086772	1002	1010	injected	T169	C0449894
28086772	1018	1021	SBE	T123	C1999758
28086772	1022	1029	treated	T169	C1522326
28086772	1030	1034	mice	T015	C0025929
28086772	1040	1043	day	T079	C0439228
28086772	1046	1050	post	T079	C0687676
28086772	1051	1054	H22	T025	C0677626
28086772	1055	1066	inoculation	T061	C2987620
28086772	1082	1088	effect	T080	C1280500
28086772	1092	1104	tumor growth	T191	C0598934
28086772	1106	1109	SBE	T123	C1999758
28086772	1110	1119	treatment	T169	C1522326
28086772	1120	1129	inhibited	T080	C0311403
28086772	1134	1147	proliferation	T043	C0596290
28086772	1151	1162	HepG2 cells	T025	C2717940
28086772	1163	1171	in vitro	T080	C1533691
28086772	1179	1200	dose-dependent manner	T169	C0205245
28086772	1219	1229	suppressed	T169	C1260953
28086772	1234	1246	tumor growth	T191	C0598934
28086772	1250	1262	hepatoma H22	T025	C0677626
28086772	1272	1276	mice	T015	C0025929
28086772	1292	1301	increased	T081	C0205217
28086772	1302	1324	NK cells' cytotoxicity	T043	C1159807
28086772	1328	1334	spleen	T023	C0037993
28086772	1336	1350	down-regulated	T044	C0013081
28086772	1355	1361	amount	T081	C1265611
28086772	1365	1397	CD4(+)CD25(+)Foxp3(+) Treg cells	T121	C3830403
28086772	1402	1412	Th17 cells	T025	C2936411
28086772	1416	1428	tumor tissue	T024	C0475358
28086772	1434	1443	decreased	T081	C0205216
28086772	1444	1449	IL-10	T116,T129	C3179724
28086772	1451	1456	TGF-β	T116,T129,T192	C0076930
28086772	1462	1468	IL-17A	T116,T192	C1705947
28086772	1469	1475	levels	T080	C0441889
28086772	1495	1504	increased	T081	C0205217
28086772	1505	1509	IL-2	T116,T129	C0021756
28086772	1514	1519	IFN-γ	T116,T192	C0211279
28086772	1520	1526	levels	T080	C0441889
28086772	1545	1550	serum	T031	C0229671
28086772	1554	1566	hepatoma H22	T025	C0677626
28086772	1576	1580	mice	T015	C0025929
28086772	1592	1606	administration	T081	C0001555
28086772	1610	1627	recombinant mouse	T015	C0025929
28086772	1628	1634	IL-17A	T116,T192	C1705947
28086772	1635	1643	reversed	T169	C1555029
28086772	1648	1658	anti-tumor	T080	C2986475
28086772	1659	1666	effects	T080	C1280500
28086772	1670	1673	SBE	T123	C1999758
28086772	1675	1678	SBE	T123	C1999758
28086772	1685	1692	inhibit	T052	C3463820
28086772	1697	1710	proliferation	T043	C0596290
28086772	1714	1725	HepG2 cells	T025	C2717940
28086772	1726	1734	in vitro	T080	C1533691
28086772	1747	1750	SBE	T123	C1999758
28086772	1762	1769	inhibit	T052	C3463820
28086772	1774	1780	growth	T043	C0007595
28086772	1784	1787	H22	T025	C0677626
28086772	1788	1803	implanted tumor	T191	C0027651
28086772	1807	1819	hepatoma H22	T025	C0677626
28086772	1829	1833	mice	T015	C0025929
28086772	1844	1852	function	T169	C0542341
28086772	1862	1877	associated with	T080	C0332281
28086772	1878	1903	immunomodulatory activity	T044	C1148560
28086772	1912	1927	down-regulating	T044	C0013081
28086772	1931	1941	Treg cells	T025	C0039198
28086772	1946	1958	manipulating	T040	C2584326
28086772	1959	1962	Th1	T043	C1155080
28086772	1965	1985	Th17 immune response	T040	C3156592